Diversifying clinical trials.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30523324.
- Also identified by DOI 10.1038/s41591-018-0303-4.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Scientific common sense and social justice dictate that the safety and efficacy of new therapies must be tested in the patient populations in need of treatment. Yet a recent study found that African Americans have been dramatically underrepresented in US clinical trials for cancer drugs. Efforts to increase the participation of minorities in clinical trials must become a priority for all drug developers.
Medical subject headings
- Black or African American
- Clinical Trials as Topic
- Drug Development